Studies Suggest Yaz Associated with Increased Risk of Blood Clots

Share This:

Two new studies published last week by the British Medical Journal suggest that taking newer, “fourth generation” birth control pills may bring a higher risk of blood clots than previous pills. These newer pills, sold under the brand names Yaz or Yasmin, contain drospirenone, a new type of progestogen hormone associated with two to three times the risk of blood clots when compared to traditional levonorgestrel-containing pills.

The first study conducted at the Boston University of Medicine found that women aged 25 to 44 taking Yaz or Yasmin had a 2.3 times greater risk of suffering from blood clots – 30.8 per 100,000 women taking drospirenone (Yaz), compared to 12.5 per 100,000 for those on levonorgestrel. A study from the United Kingdom on women in the same age group found a three times greater risk – 23 per 100,000 women for the drospirenone group and 9.1 per 100,000 women taking levonorgestrel.

Despite the increased risk associated with Yaz and Yasmin, the overall chance of suffering a blood clot remains very small. Dr. Steven R. Goldstein, professor of obstetrics and gynecology at NYU, has stated that the findings may affect his prescribing of Yaz to new patients, but it would not force him to remove the birth control drug from current users that are doing well and have no family history of blood clots.

While this news of these studies is unlikely to make any major waves in birth control prescription practices, it reinforces the fact that people at an increased risk for blood clots should steer clear of birth control pills altogether.

Have you or a loved suffered harm as a result of a Yaz or Yasmin prescription? A Yaz attorney may be able to help counsel you with your situation.